

Rating Advisory

November 16, 2021 | Mumbai

Acme Generics LLP

Advisory as on November 16, 2021

This rating advisory is provided in relation to the rating of Acme Generics LLP

The key rating sensitivity factors for the rating include:

Upward factor

- Improvement in revenue by 30% along with improvement in margins, leading to higher than expected cash accruals.
- Earlier than expected reduction in investments in group companies leading to further strengthening of financial risk profile

Downward factor

- Witnesses a substantial increase in its working capital requirements thus weakening its liquidity & financial profile
- Decline in operating profitability or scale leading to cash accruals of the group at below Rs 25 Cr

CRISIL Ratings has a policy of keeping its accepted ratings under constant and ongoing monitoring and review. Accordingly, it seeks regular updates from companies on business and financial performance. CRISIL Ratings is yet to receive adequate information from Acme Generics LLP (AGL) to enable it to undertake a rating review. CRISIL Ratings is taking all possible efforts to get the rated entity to cooperate with its rating process for enabling it to carry out the rating review.

CRISIL Ratings views information availability risk as a key factor in its assessment of credit risk. (Please refer to CRISIL Ratings' criteria available at the following link, https://www.crisil.com/content/dam/crisil/criteria_methodology/basics-of-ratings/assessing-information-adequacy-risk.pdf)

If AGL continues to delay the provisioning of information required by CRISIL Ratings to undertake a rating review then, in accordance with circulars SEBI/HO/MIRSD/MIRSD4/CIR/P/2016/119 dt Nov 1, 2016, SEBI/HO/MIRSD/MIRSD4/CIR/P/2017/71 dt June 30, 2017 and **SEBI/HO/MIRSD/CRADT/CIR/P/2020/2 dt January 3, 2020** issued by Securities and Exchange Board of India, CRISIL Ratings will carry out the review based on best available information and issue a press release.

About The Company

Acme Formulation Pvt Ltd

AFPL; part of JCBL Group, was incorporated in 2004. AFPL is engaged in providing contract dosage which includes capsules and hormonal tablets. AFPL is promoted by Mr. Viral Shah.

Acme Generics LLP

AGL was incorporated in 2014 as a partnership firm. It is also engaged in providing contract dosage which includes capsules and hormonal tablets and is owned by Acme Formulation Pvt Ltd and Mr. Viral Shah.

About the Group

Began in 2005, ACME group is engaged in providing integrated contract manufacturing and development solutions to top Indian and global pharmaceutical companies. The group consist of two companies viz. Acme Formulation Private Limited and AGL. The group has also expanded into niche segments of Oral Hormones, both Sex Hormones and Levothyroxine, along with General Injectables - Liquids and Lyophilized.

About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ("CRISIL Ratings") is a wholly-owned subsidiary of CRISIL Limited ("CRISIL"). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com

About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide

For more information, visit www.crisil.com

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.

DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale (each a "Report") that is provided by CRISIL Ratings Limited (hereinafter referred to as "CRISIL Ratings"). For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. Rating by CRISIL Ratings contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way. CRISIL Ratings or its associates may have other commercial transactions with the company/entity.

Neither CRISIL Ratings nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Ratings Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Ratings Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL RATINGS' PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL Rating's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: <http://www.crisil.com/ratings/highlightedpolicy.html>

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL Ratings you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings Limited is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html

Pursuant to SEBI notifications, CRISIL Limited (CRISIL) has transferred its Ratings business to its wholly owned subsidiary, CRISIL Ratings Limited (CRISIL Ratings), with effect from December 31st 2020. Any reference to CRISIL in the documents published by the Ratings division of CRISIL, such as Rating Rationales, Credit Rating Reports, Press Releases, Criteria, Methodology, FAQs, Policies and Disclosures, shall henceforth refer to CRISIL Ratings.

Rating Rationale

January 08, 2021 | Mumbai

ACME Generics LLP

Ratings migrated to 'CRISIL BBB- / Stable'

Rating Action

Total Bank Loan Facilities Rated	Rs.85 Crore
Long Term Rating ^{&}	CRISIL BBB-/Stable (Migrated from 'CRISIL B+/Stable ISSUER NOT COOPERATING*')

[&] * - Issuer did not cooperate; based on best-available information

1 crore = 10 million

Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

Due to inadequate information, CRISIL Ratings, in line with SEBI guidelines, had migrated its rating on bank facilities of ACME Generics LLP (AGL; part of Acme group) to 'CRISIL B+/Stable; issuer not cooperating'. However, the management has subsequently started sharing the information, necessary for carrying out a comprehensive review of the rating. Consequently, CRISIL Ratings is migrating the rating to '**CRISIL BBB-/Stable**'

Business risk profile of the group is marked by healthy scale of operations as indicated by turnover of around Rs 377 Cr in FY20. Revenue is expected to increase at healthy pace over medium term on the back of increase in export business. Though, operating margins moderated to 13.5% in fiscal 20 from 17.7% in fiscal 18, yet it remains healthy. Financial risk profile is marked by strong net-worth of around Rs 217 Cr in FY20, comfortable gearing of 0.47 time and healthy debt protection metrics marked by interest coverage of 6 times for fiscal 2020. However, significant investments in the group companies constrains the financial risk profile. Liquidity remains adequate marked by moderate BLU of around 30%, healthy accruals against repayments and healthy unencumbered cash balance.

The rating action also factors the corporate guarantee worth Rs. 119.7 crore (as on March 31, 2020) extended by AFPL to group companies like ACME Generics LLP (AGL) and Immacule Lifesciences Private Limited (ILPL). As indicated by management, corporate guarantee to ILPL is expected to be withdrawn in near term and management structure is also expected to be simplified between key promoters Viral Shah and JCBL India Private Limited in near to medium term.

The rating also reflects the group's established market position and sound operating efficiencies. These strengths are partially offset by its susceptibility to any adverse impact of regulatory changes and significant investment to group entities.

Analytical Approach: For arriving at the ratings, CRISIL has combined the business and financial risk profiles of AFPL & ACME Generics LLP (AGL). This is because all these entities, together referred as the Acme group, operate in the same industry and have operational and financial linkages. CRISIL has not combined the financial and business risk profile of Immacule Lifesciences Private Limited as the corporate guarantee extended by AFPL to ILPL is expected to be withdrawn within 1-2 months.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

*** Established market position:** The group moderate scale provides it an operating flexibility in an intensely competitive industry. Further, it also benefits from the promoters' experience of over a decade. Their strong understanding of market dynamics, and healthy relations with customers and suppliers will continue to support the business.

*** Comfortable Financial Risk Profile:** The group has healthy financial risk profile marked by healthy network of Rs 217 Cr in fiscal 2020. Gearing also remained comfortable at around 0.47 time and is expected to improve with stable accretion to reserves and repayment of debt. Debt protection metrics also remained healthy marked by interest coverage of above 6 times in fiscal 2020.

Weaknesses:

* **Susceptibility to any adverse impact of regulatory changes:** Changes such as Goods and Service Tax, Demonetization, the ban on 344 fixed-dose combinations in fiscal 2016 and revision in the drug price control order in 2013, which brought more drugs under price control, impacted the pharmaceutical industry adversely. Hence, the operating margin and scale of operations remains susceptible to such regulatory changes in India or in overseas territory.

* **Significant Investments in Group Entities:** The group has extended investments of above Rs. 100 crore in group entities and has also extended corporate guarantees of Rs. 119.7 crore to its group entities ILPL and AGL which acts as a constraining factor to the overall financial risk profile.

Liquidity: Adequate

Bank limit utilisation is low at around 29 percent for the past twelve months ended September 2020. Cash accrual are expected to be over Rs 48 Cr which are sufficient against term debt obligation of Rs 16 Cr over the medium term. Surplus accruals are expected to aid liquidity further. Current ratio are moderate at 1 times on March 31, 2020.

Outlook Stable

CRISIL believe the Acme group will continue to benefit from the extensive experience of its promoter, and established relationships with clients.

Rating Sensitivity factors**Upward factor**

- Improvement in revenue by 30% along with improvement in margins, leading to higher than expected cash accruals.
- Earlier than expected reduction in investments in group companies leading to further strengthening of financial risk profile

Downward factor

- Witnesses a substantial increase in its working capital requirements thus weakening its liquidity & financial profile
- Decline in operating profitability or scale leading to cash accruals of the group at below Rs 25 Cr

About the Company**Acme Formulation Pvt Ltd**

AFPL; part of JCBL Group, was incorporated in 2004. AFPL is engaged in providing contract dosage which includes capsules and hormonal tablets. AFPL is promoted by Mr. Viral Shah.

Acme Generics LLP

AGL was incorporated in 2014 as a partnership firm. It is also engaged in providing contract dosage which includes capsules and hormonal tablets and is owned by Acme Formulation Pvt Ltd and Mr. Viral Shah.

About the Group

Began in 2005, ACME group is engaged in providing integrated contract manufacturing and development solutions to top Indian and global pharmaceutical companies. The group consist of two companies viz. Acme Formulation Private Limited and AGL. The group has also expanded into niche segments of Oral Hormones, both Sex Hormones and Levothyroxine, along with General Injectables - Liquids and Lyophilized.

Key Financial Indicators**Consolidated nos. (Crisil Adjusted Nos.)**

As on / for the period ended March 31		2020	2019
Operating income	Rs crore	377	378
Reported profit after tax	Rs crore	23	25
PAT margins	%	6.2	6.7
Adjusted Debt/Adjusted Net worth	Times	0.47	0.56
Interest coverage	Times	6.07	5.89

Standalone Nos.

AFPL		2020	2019
As on / for the period ended March 31		2020	2019
Operating income	Rs crore	144.42	120.18
Reported profit after tax	Rs crore	13.26	10.83
PAT margins	%	9.18	9.02
Adjusted Debt/Adjusted Net worth	Times	0.22	0.18
Interest coverage	Times	7.59	7.35

AGL		2020	2019
As on / for the period ended March 31		2020	2019

Operating income	Rs crore	232.54	257.48
Reported profit after tax	Rs crore	10.08	14.62
PAT margins	%	4.3	5.7
Adjusted Debt/Adjusted Net worth	Times	0.68	0.97
Interest coverage	Times	4.63	4.68

Status of non cooperation with previous CRA: AGL has not cooperated with ICRA Limited, which led to its classification as 'issuer not cooperative' vide release dated Nov 20, 2020. The reason provided by ICRA Limited is non-furnishing of information for monitoring of ratings

Any other information: Not applicable

Note on complexity levels of the rated instrument:

CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN	Name of instrument	Date of allotment	Coupon rate (%)	Maturity date	Issue size (Rs crore)	Complexity Levels	Rating assigned with outlook
NA	Cash Credit	NA	NA	NA	10	NA	CRISIL BBB-/Stable
NA	Term Loan	NA	NA	Mar-25	75	NA	CRISIL BBB-/Stable

Annexure – List of entities consolidated

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
Acme Formulation Private Limited, ACME Generics LLP	Full	All the companies, collectively referred to as the Acme Group, have the same promoter, Mr. Viral Shah and a common management team; are in the same line of business and have operational linkages and fungible cash flows.

Annexure - Rating History for last 3 Years

Instrument	Current			2021 (History)		2020		2019		2018		Start of 2018
	Type	Outstanding Amount	Rating	Date	Rating	Date	Rating	Date	Rating	Date	Rating	Rating
Fund Based Facilities	LT	85.0	CRISIL BBB-/Stable		--	21-01-20	CRISIL B+ /Stable(Issuer Not Cooperating)*		--	25-10-18	CRISIL B+ /Stable(Issuer Not Cooperating)*	CRISIL B+ /Stable(Issuer Not Cooperating)*

All amounts are in Rs.Cr.

* - Issuer did not cooperate; based on best-available information

Annexure - Details of various bank facilities

Current facilities			Previous facilities		
Facility	Amount (Rs.Crore)	Rating	Facility	Amount (Rs.Crore)	Rating
Cash Credit	10	CRISIL BBB-/Stable	Cash Credit	10	CRISIL B+ /Stable/Issuer Not Cooperating
Term Loan	75	CRISIL BBB-/Stable	Term Loan	75	CRISIL B+ /Stable/Issuer Not Cooperating
Total	85	-	Total	85	-

Links to related criteria

[CRISILs Approach to Financial Ratios](#)

[Rating criteria for manufacturing and service sector companies](#)

[CRISILs Bank Loan Ratings - process, scale and default recognition](#)

[Assessing Information Adequacy Risk](#)

[Rating Criteria for the Pharmaceutical Industry](#)

[CRISILs Criteria for Consolidation](#)

Media Relations	Analytical Contacts	Customer Service Helpdesk
<p>Saman Khan Media Relations CRISIL Limited D: +91 22 3342 3895 B: +91 22 3342 3000 saman.khan@crisil.com</p> <p>Naireen Ahmed Media Relations CRISIL Limited D: +91 22 3342 1818 B: +91 22 3342 3000 naireen.ahmed@crisil.com</p>	<p>Nitin Kansal Director CRISIL Ratings Limited D:+91 124 672 2154 nitin.kansal@crisil.com</p> <p>Akshita Jain Associate Director CRISIL Ratings Limited D:+91 124 672 2189 Akshita.Jain@crisil.com</p> <p>Vaibhav Gupta Rating Analyst CRISIL Ratings Limited B:+91 20 4018 1900 Vaibhav.Gupta@crisil.com</p>	<p>Timings: 10.00 am to 7.00 pm Toll free Number:1800 267 1301</p> <p>For a copy of Rationales / Rating Reports: CRISILratingdesk@crisil.com</p> <p>For Analytical queries: ratingsinvestordesk@crisil.com</p>

Note for Media:

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.

About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

About CRISIL Ratings

CRISIL Ratings is part of CRISIL Limited ("CRISIL"). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI"). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 95,000 MSMEs have been rated by us.

CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the "Company") you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit www.crisil.com/privacy. You can view the Company's Customer Privacy at <https://www.spglobal.com/privacy>

Last updated: April 2016

DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a "Report"). For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: <http://www.crisil.com/ratings/highlightedpolicy.html>

CRISIL's rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL

CRISIL uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL's use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html